The treatment of VAIHS in patients with bi‐allelic ADA2 pathogenic variants to relieve autoinflammatory/vasculitis manifestations reduces the risk of stroke and relieves immunodeficiency involves anti‐tumor‐necrosis factor (TNF) agents such as etanercept, adalimumab, golimumab, infliximab, and certolizumab, although anti‐TNF agents may not have any impact on severe bone marrow abnormalities.8, 9. Here, ADA2 is linked to immunodeficiency disease.